Reanalyses of Randomized Clinical Trial Data

被引:127
|
作者
Ebrahim, Shanil [1 ,2 ,3 ,4 ]
Sohani, Zahra N. [2 ,5 ]
Montoya, Luis [6 ]
Agarwal, Arnav [7 ]
Thorlund, Kristian [1 ,2 ]
Mills, Edward J. [1 ,2 ,8 ]
Ioannidis, John P. A. [1 ,9 ,10 ,11 ]
机构
[1] Stanford Univ, Dept Med, Stanford Prevent Res Ctr, Stanford, CA 94305 USA
[2] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada
[3] McMaster Univ, Dept Anesthesia, Hamilton, ON L8S 4L8, Canada
[4] Hosp Sick Children, Dept Anaesthesia & Pain Med, Toronto, ON M5G 1X8, Canada
[5] McMaster Univ, Populat Genom Program, Hamilton, ON L8S 4L8, Canada
[6] Univ Hlth Network, Toronto, ON, Canada
[7] McMaster Univ, Fac Hlth Sci, Hamilton, ON L8S 4L8, Canada
[8] Univ Ottawa, Fac Hlth Sci, Ottawa, ON, Canada
[9] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA
[10] Stanford Univ, Sch Humanities & Sci, Dept Stat, Stanford, CA 94305 USA
[11] Stanford Univ, Meta Res Innovat Ctr Stanford METRICS, Stanford, CA 94305 USA
来源
基金
加拿大健康研究院;
关键词
PERIPHERAL NEUROPATHY; EFFICACY CRITERIA; NATIONAL-SURVEY; ACUPUNCTURE; GENETICS; SCIENCE; DISEASE; MODEL;
D O I
10.1001/jama.2014.9646
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE Reanalyses of randomized clinical trial (RCT) data may help the scientific community assess the validity of reported trial results. OBJECTIVES To identify published reanalyses of RCT data, to characterize methodological and other differences between the original trial and reanalysis, to evaluate the independence of authors performing the reanalyses, and to assess whether the reanalysis changed interpretations from the original article about the types or numbers of patients who should be treated. DESIGN We completed an electronic search of MEDLINE from inception to March 9, 2014, to identify all published studies that completed a reanalysis of individual patient data from previously published RCTs addressing the same hypothesis as the original RCT. Four data extractors independently screened articles and extracted data. MAIN OUTCOMES AND MEASURES Changes in direction and magnitude of treatment effect, statistical significance, and interpretation about the types or numbers of patients who should be treated. RESULTS We identified 37 eligible reanalyses in 36 published articles, 5 of which were performed by entirely independent authors (2 based on publicly available data and 2 on data that were provided on request; data availability was unclear for 1). Reanalyses differed most commonly in statistical or analytical approaches (n = 18) and in definitions or measurements of the outcome of interest (n = 12). Four reanalyses changed the direction and 2 changed the magnitude of treatment effect, whereas 4 led to changes in statistical significance of findings. Thirteen reanalyses (35%) led to interpretations different from that of the original article, 3 (8%) showing that different patients should be treated; 1 (3%), that fewer patients should be treated; and 9 (24%), that more patients should be treated. CONCLUSIONS AND RELEVANCE A small number of reanalyses of RCTs have been published to date. Only a few were conducted by entirely independent authors. Thirty-five percent of published reanalyses led to changes in findings that implied conclusions different from those of the original article about the types and number of patients who should be treated.
引用
收藏
页码:1024 / 1032
页数:9
相关论文
共 50 条
  • [41] The mixed randomized trial: combining randomized, pragmatic and observational clinical trial designs
    Alsop, Jonathan
    Scott, Martin
    Archey, William
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2016, 5 (06) : 569 - 579
  • [42] Beyond the Randomized Clinical Trial: Innovative Data Science to Close the Pediatric Evidence Gap
    Goulooze, Sebastiaan
    Zwep, Laura B.
    Vogt, Julia E.
    Krekels, Elke H. J.
    Hankemeier, Thomas
    van den Anker, Johannes N.
    Knibbe, Catherijne A. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 (04) : 786 - 795
  • [43] Defining responders to therapies by a statistical modeling approach applied to randomized clinical trial data
    Francesca Bovis
    Luca Carmisciano
    Alessio Signori
    Matteo Pardini
    Joshua R. Steinerman
    Thomas Li
    Aaron P. Tansy
    Maria Pia Sormani
    BMC Medicine, 17
  • [44] Lamotrigine for juvenile myoclonic epilepsy: Analysis of data from a randomized, controlled clinical trial
    Trevathan, E.
    Kerls, S. P.
    Hammer, A. E.
    Voung, A.
    Messenheimer, J. A.
    ANNALS OF NEUROLOGY, 2006, 60 : S118 - S118
  • [45] Simple subgroup approximations to optimal treatment regimes from randomized clinical trial data
    Foster, Jared C.
    Taylor, Jeremy M. G.
    Kaciroti, Niko
    Nan, Bin
    BIOSTATISTICS, 2015, 16 (02) : 368 - 382
  • [46] Rapid cycling and antidepressants: Data from a STEP-BD randomized clinical trial
    Whitham, E. A.
    Thommi, S. B.
    Holtzman, N. S.
    Ostacher, M. M.
    El-Mallakh, R. S.
    Baldassano, C. F.
    Filkowski, M. M.
    Goodwin, F. K.
    Baldessarini, R. J.
    Ghaemi, S. N.
    BIPOLAR DISORDERS, 2011, 13 : 106 - 106
  • [47] Release of data from an ongoing randomized clinical trial for sample size adjustment or planning
    Freidlin, Boris
    Korn, Edward L.
    STATISTICS IN MEDICINE, 2007, 26 (22) : 4074 - 4082
  • [48] Lamotrigine for juvenile myoclonic epilepsy: Analysis of data from a randomized, controlled clinical trial
    Trevathan, E
    Kerls, SP
    Hammer, AE
    Vuong, A
    Messenheimer, JA
    NEUROLOGY, 2006, 66 (05) : A38 - A38
  • [49] Defining responders to therapies by a statistical modeling approach applied to randomized clinical trial data
    Bovis, Francesca
    Carmisciano, Luca
    Signori, Alessio
    Pardini, Matteo
    Steinerman, Joshua R.
    Li, Thomas
    Tansy, Aaron P.
    Sormani, Maria Pia
    BMC MEDICINE, 2019, 17 (1)
  • [50] Lamotrigine for juvenile myoclonic epilepsy: Analysis of data from a randomized controlled clinical trial
    Trevathan, E
    Kerls, SP
    Hammer, AE
    Vuong, A
    Messenheimer, JA
    EPILEPSIA, 2005, 46 : 219 - 219